FOLH1 and neoplasm: These results prompted a subsequent study by McInnes et al., who demonstrated that [67Cu]Cu-SAR-bisPSMA achieved therapeutic outcomes comparable to [177Lu]Lu-PSMA-I&T, with both single and fractionated administrations leading to significant tumor growth inhibition and improved survival [128].